Pharmaceutical aspects of docetaxel

American Journal of Health-System Pharmacy

Volumn 54, Issue SUPPL. 2, 1997, Pages

  Kraynak, Maura A ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

Antineoplastic agents; Clinical studies; Compounding; Containers; Diethylhexyl phthalate; Docetaxel; Dosage; Formulations; Injections; Leaching; Pharmacokinetics; Plasticizers; Plastics; Polyvinyl chloride; Stability; Storage

Indexed keywords

DOCETAXEL; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PLASTICIZER; POLYVINYLCHLORIDE;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER RESISTANCE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; DRUG PACKAGING; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; HUMAN; INFUSION SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; LEACHING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY;

EID: 0031473804     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.suppl_2.s7     Document Type: Conference Paper

References (17)

1. Denis JN, Greene AE, Guénard D et al. A highly efficient, practical approach to natural taxol. J Am Chem Soc. 1988; 110:5917-9.
2. Mangatal L, Adeline MT, Guénard D et al. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron. 1989; 45:177-90.
3. Extra JM, Rousseau F, Bruno R et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 1993; 53:1037-42.
4. Aapro MS, Zullan G, Alberto P et al. Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of Taxotere. Ann Oncol. 1992; 3(suppl 5):53. Abstract.
5. Bissett D, Setanoians A, Cassidy J et al. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. 1993; 53:523-7.
6. Pazdur R, Newman RA, Newman BM et al. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst. 1992; 84:1781-8.
7. Burris H, Irvin R, Kuhn J et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol. 1993; 11:950-8.
8. Tomiak E, Piccart M, Kerger S et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994; 12:1458-67.
9. Launay-Iliadls MC, Bruno R, Casson V et al. Population pharmacokinetics of docetaxel during Phase I studies using nonlinear mixed effect modelling and nonparametric maximum likelihood estimations. Cancer Chemother Pharmacol. 1995; 37(1-2):47-54.
10. Ravdin PM, Burris HA, Cook Get al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. j Clin Oncol. 1995; 13:2879-85.
11. Valero V, Holmes F, Walters RS et al. Phase II trial of docetaxel: a new, highly effective agent in the treatment of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13:2886-94.
12. Piccart M. Docetaxel: a new defense in the management of breast cancer. Anticancer Drugs. 1995; 6(suppl 6):7-11.
13. Nguyen-Huu JJ, Bousquet O, Bobee JM. Compatibility of Taxotere infusion solution with intravenous administration/extension sets. Paper presented at International Symposium on Oncology Pharmacy Practice. Sydney, Australia; 1997 Apr.
14. Trissel LA, Xu Q, Kwan J et al. Compatibility of paclitaxel injection vehicle with intravenous administration and extension sets. Am J Hosp Pharm. 1994; 51:2804-10.
15. Nguyen-Huu JJ, Pagniez S, Bobee JM et al. Compatibility of docetaxel infusion solutions with polivinyl chloride infusion materials. Paper presented at International Symposium on Oncology Pharmacy Practice. Sydney, Australia: 1997 Apr.
16. Mazzo DJ, Nguyen-Huu JJ, Pagniez S et al. Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am J Health-Syst Pharm. 1997; 54:566-9.
17. Taxotere package insert. Collegeville, PA: Rhône-Poulenc Rorer; 1996 May.